LOS ANGELES--(BUSINESS WIRE)--Lundin Law PC, a shareholder rights firm, announces that it is investigating claims against Exact Sciences Corporation (“Exact Sciences” or the “Company”) (Nasdaq: EXAS) concerning possible violations of federal securities laws.
To get more information about this investigation, please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or by email at email@example.com.
On May 15, 2017, Citron Research issued a report on Exact Sciences stating that: “Exact Sciences pushes a cancer test (Cologuard) to the public, inferior by its own admission, and loses money doing it.” Cologuard is a branded laboratory-based scan for DNA traces in stool samples, indicating colorectal cancer. Citron cited a recent report from United Healthcare, the biggest managed healthcare company in the US, that criticized the use of fecal DNA testing for colorectal cancer screening and monitoring. Citron added that “key metrics not disclosed by Exact Sciences are getting worse, while Medicare pricing inefficiencies end next January and investors will be left with a decaying asset with no terminal value.” Citron went on to say that “Poop in a box will probably be a medical dinosaur in 4 years and the value of Exact’s only asset will be 0.”
Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.